Open Access Peer-reviewed Research Article

Main Article Content

Jiahao Qiu corresponding author
Qianwen Ren
Yingjie Wang
Qunling Xie
Yanjie Liu
Pengfei Yu
Hongbo Wang
Jingwei Tian


Activation of DNA damage repair pathways in tumor cells may reduce the treatment efficacy of platinum-based chemotherapeutic agents. Ubiquitin-specific protease 7 (USP7) is one of the deubiquitinating enzymes that can remove the ubiquitin from target proteins and protect substrate proteins from degradation. Although ubiquitin-specific protease 7(USP7) is highly expressed in cervical cancer tissues and plays an important role in DNA damage repair, the role of USP7 inhibition in the antitumor efficacy of cisplatin remains unknown. This study explored the effects and mechanisms of a USP7 inhibitor P22077 on the anti-cervical cancer efficacy of cisplatin. In in vitro studies, P22077 and cisplatin both significantly reduced HeLa cell proliferation and colony formation, and the combination produced preferable effects. In in vivo xenograft tumor model, P22077 and cisplatin both demonstrated significant antitumor efficacy. The drug combination produced greater antitumor activity than the individual drug alone. Cisplatin evoked DNA damage repair-related molecules and P22077 tended to prevent this change. The drug combination produced higher cell death rate than the individual drug alone. Collectively, These results suggest that the USP7 inhibitor P22077 alone has significant antitumor efficacy and also can enhance the antitumor effects of cisplatin. The USP7 inhibitor P22077 combined with cisplatin may be an effective treatment strategy for cervical cancer.

cervical cancer, DNA damage repair, combination therapy strategy

Article Details

How to Cite
Qiu, J., Ren, Q., Wang, Y., Xie, Q., Liu, Y., Yu, P., Wang, H., & Tian, J. (2022). P22077 enhances the antitumor efficacy of Cisplatin and its mechanism. Journal of Pharmaceutical and Biopharmaceutical Research, 3(2), 218-227.


  1. Roden RBS and Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nature Reviews Cancer, 2018, 18(4): 240-254.
  2. Tsu V and Jeronimo J. Saving the World’s Women from Cervical Cancer. New England Journal of Medicine, 2016, 374(26): 2509-2511.
  3. Olawaiye AB, Baker TP, Washington MK, et al. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA: A Cancer Journal for Clinicians, 2021, 71(4): 287-298.
  4. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
  5. Wieringa HW, van der Zee AG, de Vries EG, et al. Breaking the DNA damage response to improve cervical cancer treatment. Cancer Treatment Review, 2016, 42: 30-40.
  6. Zhu H, Luo H, Zhang W, et al. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Development and Therapy, 2016, 10: 1885-1895.
  7. Gottesman MM, Fojo T and Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer, 2002, 2(1): 48-58.
  8. Zisowsky J, Koegel S, Leyers S, et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochemical Pharmacology, 2007, 73(2): 298-307.
  9. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22(47): 7265-7279.
  10. Dasari S and Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology, 2014, 740: 364-378.
  11. Khanna KK and Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genetics, 2001, 27(3): 247-254.
  12. Stracker TH and Petrini JH. The MRE11 complex: starting from the ends. Nature Reviews Molecular Cell Biology, 2011, 12(2): 90-103.
  13. Cherry SM, Adelman CA, Theunissen JW, et al. The Mre11 complex influences DNA repair, synapsis, and crossing over in murine meiosis. Current Biology, 2007, 17(4): 373-378.
  14. Reverdy C, Conrath S, Lopez R, et al. Discovery of Specific Inhibitors of Human USP7/HAUSP Deubiquitinating Enzyme. Chemistry & Biology, 2012, 19(4): 467-477.
  15. Uziel T, Lerenthal Y, Moyal L, et al. Requirement of the MRN complex for ATM activation by DNA damage. EMBO Journal, 2003, 22(20): 5612-5621.
  16. Jungmichel S, Clapperton JA, Lloyd J, et al. The molecular basis of ATM-dependent dimerization of the Mdc1 DNA damage checkpoint mediator. Nucleic Acids Research, 2012, 40(9): 3913-3928.
  17. Stewart GS, Wang B, Bignell CR, et al. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature, 2003, 421(6926): 961-966.
  18. Dikic I, Wakatsuki S and Walters KJ. Ubiquitin-binding domains - from structures to functions. Nature Reviews Molecular Cell Biology, 2009, 10(10): 659-6571.
  19. Vucic D, Dixit VM and Wertz IE. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nature Reviews Molecular Cell Biology, 2011, 12(7): 439-452.
  20. Wang Z, Kang W, You Y, et al. USP7: Novel Drug Target in Cancer Therapy. Frontiers in Pharmacology, 2019, 10: 427.
  21. Zhu Q, Sharma N, He J, et al. USP7 deubiquitinase promotes ubiquitin-dependent DNA damage signaling by stabilizing RNF168. Cell Cycle, 2015, 14(9): 1413-1425.
  22. Zhang P,Wei Y,Wang L, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nature Cell Biology, 2014, 16(9): 864-875.
  23. Alonso-de Vega I, Martin Y and Smits VA. USP7 controls Chk1 protein stability by direct deubiquitination. Cell Cycle, 2014, 13(24): 3921-3926.
  24. Faustrup H, Bekker-Jensen S, Bartek J, et al. USP7 counteracts SCFbetaTrCP- but not APCCdh1- mediated proteolysis of Claspin. Journal of Cell Biology, 2009, 184(1): 13-19.
  25. Su D, Ma S, Shan L, et al. Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis. Journal Of Clinical Investigation, 2018, 128(10): 4280-4296.
  26. Lv G, Sun D, Zhang J, et al. Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo. Acta Pharmaceutica Sinica B, 2017, 7(1): 52-58.
  27. Li F, Liu Z, Sun H, et al. PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo. Acta Pharmaceutica Sinica B, 2020, 10(2): 289- 300.
  28. Ma YT, Yang Y, Cai P, et al. A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility. Journal Of Natural Products, 2018, 81(3): 524- 533.
  29. Yang Y, Guan D, Lei L, et al. H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. Toxicology And Applied Pharmacology, 2018, 341: 98-105.
  30. Wang H, Ma X, Ren S, et al. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Molecular Cancer Therapeutics, 2011, 10(1): 69-79.
  31. Clague MJ, Urbe S and Komander D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nature Reviews Molecular Cell Biology, 2019, 20(6): 338-352.
  32. D’Arcy P, Wang X and Linder S. Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacology & Therapeutics, 2015, 147: 32-54.
  33. Mevissen TET and Komander D. Mechanisms of Deubiquitinase Specificity and Regulation. Annual Review of Biochemistry, 2017, 86: 159-192.
  34. Nicholson B and Kumar KGS. The Multifaceted Roles of USP7: New Therapeutic Opportunities. Cell Biochemistry and Biophysics, 2011, 60(1-2): 61-68.
  35. Turnbull AP, Ioannidis S, Krajewski WW, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature, 2017, 550(7677): 481-486.
  36. Xu L, Wang J, Yuan XN, et al. IU1 suppresses proliferation of cervical cancer cells through MDM2 degradation. International Journal of Biological Sciences, 2020, 16(15): 2951-2963.
  37. Tavana O and Gu W. Modulation of the p53/MDM2 interplay by HAUSP inhibitors. Journal of Molecular Cell Biology, 2017, 9(1): 45-52.
  38. Li M, Brooks CL, Kon N, et al. A dynamic role of HAUSP in the p53-Mdm2 pathway. Molecular Cell, 2004, 13(6): 879-886.
  39. Zlatanou A, Sabbioneda S, Miller ES, et al. USP7 is essential for maintaining Rad18 stability and DNA damage tolerance. Oncogene, 2016, 35(8): 965-976.
  40. Agathanggelou A, Smith E, Davies NJ, et al. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. Blood, 2017, 130(2): 156-166.
  41. Singh N, Bhakuni R, Chhabria D, et al. MDC1 depletion promotes cisplatin induced cell death in cervical cancer cells. BMC Research Notes, 2020, 13(1): 146.
  42. Wang M, Zhang Y, Wang T, et al. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status. Cell Biochemistry And Biophysics, 2017, 43(5): 1755-1766.